HR Execs on the Move


 
zuChem is a leading producer of unique sugars for human health and nutrition. zuChem develops proprietary technologies for the manufacture of glycochemicals and carbohydrates for use in the food, specialty and fine chemical markets. The zuChem approach is unique, combining new proprietary technologies with the more traditional synthetic techniques. zuChem researchers have a proven track record in developing and implementing scalable, industrial quality processes.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.zuchem.com
  • 2225 W. Harrison St. Suite F
    Chicago, IL USA 60612
  • Phone: 312.997.2150

Executives

Name Title Contact Details

Similar Companies

SpecialtyScripts Pharmacy

SpecialtyScripts Pharmacy is a Fall River, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kannact

Kannact is a human-driven digital health company that provides innovative healthcare collaboration solutions to improve the lives of patients with chronic conditions.

Amino

Amino, the leading healthcare guidance platform, connects people with high-quality, cost-effective providers and benefits programs in context across the healthcare ecosystem. With more than 17B healthcare claims used to inform our actionable healthcare recommendations, Amino reduces wasteful claims spending, streamlines care routing, increases care quality, and improves member experience.

LW Consulting

LW Consulting is a Harrisburg, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Glytec System

Glytec is the insulin management software company for healthcare providers focused on improving the quality and cost of care. Its FDA-cleared titration software and proprietary algorithms power the only solution capable of delivering personalized diabetes treatment recommendations across the continuum of care, from hospital to home. With ongoing support from its team of doctors, nurses and technologists headquartered outside of Boston, Glytec improves outcomes and controls costs for the large population of patients requiring insulin treatment – including those with and without a diagnosis of diabetes.